Program
Oxycodone
Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.
Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.
Drug pageOxycodone: every studyMany companies study it; this page follows only the 64 they lead. All 209 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mundipharmaits history only | 200 open or running | phase 4since Mar 8, 2011 | Jul 27, 2007 | none ahead |
| Knoa Pharmaits history only | 120 open or running | phase 3since Apr 6, 2006 | Apr 6, 2006 | none ahead |
| Pain Therapeuticsits history only | 120 open or running | phase 3since Mar 13, 2012 | Aug 12, 2008 | none ahead |
| Pfizerits history only | 60 open or running | phase 4since Jun 8, 2007 | Jun 8, 2007 | none ahead |
| Egaletits history only | 30 open or running | phase 3since Nov 10, 2015 | Dec 2, 2008 | none ahead |
| Keenova Therapeuticsits history only | 30 open or running | phase 1since Feb 26, 2009 | Feb 26, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| biodelivery-sciences-internationalits history only | 10 open or running | phase 1since Jun 21, 2019 | Jun 21, 2019 | none ahead |
| elite-laboratories-incits history only | 10 open or running | phase 3since Feb 17, 2015 | Feb 17, 2015 | none ahead |
| gl-pharm-tech-corporationits history only | 10 open or running | phase 1since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Indivior Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 16, 2018 | Nov 16, 2018 | none ahead |
| napp-pharmaceuticals-limitedits history only | 10 open or running | phase 4since Nov 3, 2008 | Nov 3, 2008 | none ahead |
| vistapharm-incits history only | 10 open or running | phase 4since Jul 3, 2013 | Jul 3, 2013 | none ahead |
Also a collaborator on its studies: PRA Health Sciences and Grünenthal.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Feb 20, 2008.
- Feb 7, 2014Phase 1 study in HealthyPain Therapeutics · NCT02059915 · 134 enrolled · United States
- Mar 13, 2014Phase 1 study in HealthyPain Therapeutics · NCT02089295 · 18 enrolled · United States
- Apr 16, 2014Phase 1 study in HealthyPain Therapeutics · NCT02117583 · 34 enrolled · United States
- Jun 10, 2014Phase 1 study in HealthyPain Therapeutics · NCT02165930 · 17 enrolled · United States
- Oct 13, 2014Phase 3 study in Bronchiolitis Obliterans SyndromeMundipharma · NCT02321397 · 155 enrolled · Germany
- Feb 17, 2015elite-laboratories-inc’s first study: phase 3 study in Substance Withdrawal SyndromeNew to elite-laboratories-incelite-laboratories-inc · NCT02391571 · 26 enrolled · United States
- Nov 10, 2015Phase 3 study in Chronic PainEgalet · NCT02603705 · 281 enrolled · United States
- Jan 18, 2016Phase 4 study in Cancer PainMundipharma · NCT02660229 · 66 enrolled · Korea, Republic of
- Mar 8, 2016Phase 3 study in Moderate-to-severe Chronic Low Back PainEgalet · NCT02716857 · 549 enrolled · United States
- May 22, 2017Phase 4 study in NeoplasmsMundipharma · NCT03176121 · 73 enrolled · Taiwan
- Jun 1, 2017Phase 4 study in NeoplasmsMundipharma · NCT03176199 · 30 enrolled · Taiwan
- Mar 7, 2018Phase 1 study in Opioid Abuse NondependentPain Therapeutics · NCT03475862 · 38 enrolled · United States
- Nov 16, 2018Indivior Pharmaceuticals’ first study: phase 1 study in HealthyNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT03747341 · 22 enrolled · Netherlands
- Jun 21, 2019biodelivery-sciences-international’s first study: phase 1 study in Respiratory InsufficiencyNew to biodelivery-sciences-internationalbiodelivery-sciences-international · NCT03996694 · 19 enrolled · United States
TargetBeta
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| Methadonerule | Merck | phase 4 | 16 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| axelopranrule | glycyx-therapeutics | phase 2 | 8 |
| Alfentanilrule | Sichuan Kelun Pharmaceutical | phase 1 | 1 |
Studies
The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03996694Respiratory Insufficiency · United States | 1 | Completed | biodelivery-sciences-international | Oct 27, 2019 | 19 |
| NCT03747341Healthy · Netherlands | 1 | Completed | Indivior Pharmaceuticals | Jan 4, 2019 | 22 |
| NCT03475862Opioid Abuse Nondependent · United States | 1 | Completed | Pain Therapeutics | Jul 31, 2017 | 38 |
| NCT03176199Neoplasms · Taiwan | 4 | Completed | Mundipharma | Dec 31, 2018 | 30 |
| NCT03176121Neoplasms · Taiwan | 4 | Completed | Mundipharma | Dec 31, 2018 | 73 |
| NCT02716857Moderate-to-severe Chronic Low Back Pain · United States | 3 | Completed | Egalet | Aug 2017 | 549 |
| NCT02660229Cancer Pain · Korea, Republic of | 4 | Completed | Mundipharma | Jul 2016 | 66 |
| NCT02603705Chronic Pain · United States | 3 | Completed | Egalet | Jun 15, 2017 | 281 |
| NCT02391571Substance Withdrawal Syndrome · United States | 3 | Completed | elite-laboratories-inc | Mar 2015 | 26 |
| NCT02321397Bronchiolitis Obliterans Syndrome · Germany | 3 | Completed | Mundipharma | Mar 2016 | 155 |
| NCT02165930Healthy · United States | 1 | Completed | Pain Therapeutics | Aug 2014 | 17 |
| NCT02117583Healthy · United States | 1 | Completed | Pain Therapeutics | Aug 2014 | 34 |
| NCT02089295Healthy · United States | 1 | Completed | Pain Therapeutics | Jun 2014 | 18 |
| NCT02059915Healthy · United States | 1 | Completed | Pain Therapeutics | Jul 2014 | 134 |
| NCT01986283Substance-Related Disorders · United States | 1 | Completed | Pain Therapeutics | Aug 2014 | 67 |
| NCT01924676Healthy · United States | 1 | Completed | Pain Therapeutics | Oct 2013 | 18 |
| NCT01918098Non Cancer Pain · China | 3 | Completed | Mundipharma | Mar 30, 2017 | 230 |
| NCT01959204Pain · United States | 4 | Completed | vistapharm-inc | Aug 21, 2019 | 97 |
| NCT01885182Neoplasms · China | 3 | Completed | Mundipharma | Aug 30, 2015 | 232 |
| NCT01825447Healthy · United States | 1 | Completed | Pfizer | Sep 2013 | 89 |
| NCT01811186Chronic Pain · Korea, Republic of | 4 | Completed | Mundipharma | Jan 2014 | 261 |
| NCT01717027Healthy · United States | 1 | Completed | Pain Therapeutics | Jan 2013 | 19 |
| NCT01811238Spinal Disorders | 4 | Completed | Mundipharma | Apr 2013 | 240 |
| NCT01719757Neoplasms · Korea, Republic of | 4 | Completed | Mundipharma | Oct 2013 | 359 |
| NCT01675635Pain, Postoperative | 3 | Completed | Mundipharma | Jun 2012 | 240 |
| NCT01675622Neoplasms | 3 | Completed | Mundipharma | Jun 2012 | 242 |
| NCT01568450Healthy · Korea, Republic of | 1 | Completed | gl-pharm-tech-corporation | Apr 2012 | 24 |
| NCT01557257Management of Moderate to Severe Pain · United States | 1 | Completed | Pfizer | May 2012 | 13 |
| NCT01559701Pain | 3 | Completed | Pain Therapeutics | Feb 2008 | 823 |
| NCT01552863Pain · United States | 1 | Completed | Pain Therapeutics | Sep 2012 | 21 |
| NCT01552850Pain · Singapore | 1 | Completed | Pain Therapeutics | Jun 2012 | 18 |
| NCT01530542Agnosia · United States | 1 | Completed | Pfizer | Sep 2010 | 35 |
| NCT01643772Pain · China | 1 | Completed | Mundipharma | Jul 2012 | 61 |
| NCT01482936Pain · China | 1 | Completed | Mundipharma | Apr 2011 | 44 |
| NCT01439100Parkinson Disease · Czech Republic, Germany, Hungary and more | 3 | Completed | Mundipharma | Aug 2013 | 172 |
| NCT01428583Chronic Noncancer Pain · United States | 3 | Completed | Pfizer | May 2012 | 395 |
| NCT01438567Pain · United Kingdom | 3 | Completed | Mundipharma | Feb 2014 | 270 |
| NCT01369615Pain · United States, Israel | 3 | Completed | Knoa Pharma | Dec 2013 | 23 |
| NCT01313780Neoplasms · Korea, Republic of | 4 | Completed | Mundipharma | Oct 2013 | 128 |
| NCT01304134Other Acute Postoperative Pain · China | 3 | Completed | Mundipharma | Aug 2010 | 240 |
| NCT01192295Pain · United States, Greece, Hungary and more | 3 | Completed | Knoa Pharma | Jul 2014 | 155 |
| NCT01167699Pain · Belgium | 3 | Completed | Mundipharma | Apr 2011 | 174 |
| NCT01101321Healthy · United States | 1 | Completed | Knoa Pharma | Aug 2008 | 58 |
| NCT01101308Healthy · United States | 1 | Completed | Knoa Pharma | Aug 2008 | 55 |
| NCT01101191Healthy · United States | 1 | Completed | Knoa Pharma | Oct 2007 | 84 |
| NCT01101178Healthy · United States | 1 | Completed | Knoa Pharma | Nov 2007 | 79 |
| NCT01101165Healthy · United States | 1 | Completed | Knoa Pharma | Apr 2007 | 92 |
| NCT01100320Healthy Volunteers · United States | 1 | Completed | Knoa Pharma | Mar 2007 | 88 |
| NCT01100086Healthy Volunteers · United States | 1 | Completed | Knoa Pharma | Mar 2007 | 84 |
| NCT01099709Healthy Volunteers · United States | 1 | Completed | Knoa Pharma | Mar 2007 | 85 |
| NCT00864526Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 40 |
| NCT00864357Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 40 |
| NCT00853736Healthy · United States | 1 | Completed | Keenova Therapeutics | Feb 2003 | 23 |
| NCT00853320Healthy · United States | 1 | Completed | Keenova Therapeutics | Feb 2003 | 38 |
| NCT00853216Healthy · United States | 1 | Completed | Keenova Therapeutics | Feb 2003 | 38 |
| NCT00801788Pain · Canada | 1 | Completed | Egalet | Oct 2008 | 16 |
| NCT00784810Osteoarthritis · United Kingdom | 4 | Completed | napp-pharmaceuticals-limited | Mar 2010 | 247 |
| NCT00743587Osteoarthritis Thumbs · Belgium | 1 | Completed | Pfizer | Mar 2009 | 36 |
| NCT00734461Opioid-Related Disorders · United States | 2 | Completed | Pain Therapeutics | Mar 2009 | 14 |
| NCT00626600Cancer Pain · United Kingdom | 3 | Terminated | Mundipharma | May 2009 | 33 |
How it is read
Names in the registry
- “Oxycodone”, 43 entries
- “Reformulated OXY (oxycodone HCl)”, 6 entries
- “Oxycodone/Naloxone”, 5 entries
- “oxycodone hydrochloride”, 4 entries
- “Oxycodone hydrochloride”, 3 entries
Conditions, from the studies’ own filings
- Pain, 15 studies
- Neoplasms, 7 studies
- Osteoarthritis, 4 studies
- Cancer Pain, 3 studies
- Chronic Pain, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.